FY2024 EPS Estimates for Unity Biotechnology, Inc. Boosted by Analyst (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX) – Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for shares of Unity Biotechnology in a research report issued to clients and investors on Tuesday, April 16th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($2.42) per share for the year, up from their previous forecast of ($3.83). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($0.29) EPS.

Unity Biotechnology Price Performance

Unity Biotechnology stock opened at $1.51 on Thursday. The firm has a 50-day moving average of $1.66 and a two-hundred day moving average of $1.78. Unity Biotechnology has a 1 year low of $1.50 and a 1 year high of $3.82.

Institutional Investors Weigh In On Unity Biotechnology

Several hedge funds have recently modified their holdings of UBX. Vanguard Group Inc. lifted its position in shares of Unity Biotechnology by 246.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,437,259 shares of the company’s stock worth $1,753,000 after purchasing an additional 3,155,586 shares during the period. Armistice Capital LLC bought a new position in shares of Unity Biotechnology during the 4th quarter worth approximately $1,328,000. Renaissance Technologies LLC raised its stake in shares of Unity Biotechnology by 65.2% during the 3rd quarter. Renaissance Technologies LLC now owns 1,582,369 shares of the company’s stock worth $625,000 after acquiring an additional 624,651 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Unity Biotechnology by 39.8% during the 1st quarter. Acadian Asset Management LLC now owns 389,893 shares of the company’s stock worth $435,000 after acquiring an additional 111,097 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Unity Biotechnology by 28,706.0% during the 2nd quarter. Wells Fargo & Company MN now owns 43,497 shares of the company’s stock worth $111,000 after acquiring an additional 43,346 shares in the last quarter. Hedge funds and other institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.